// App-Quantinova.ai

OP0219 (2017) : EARLY ONSET OF EFFICACY WITH APREMILAST MONOTHERAPY IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: A PHASE 3B, RANDOMIZED, CONTROLLED TRIAL

Researchers

Presenter

  • P. Nash

Principal Investigators

  • K. Ohson

  • J. Walsh

  • N. Delev

  • D. Nguyen

  • L. Teng

  • J.J. Gomez-Reino

  • J.A. Aelion

Medical Centers

  • The University of Queensland, Brisbane, Australia

  • Memorial University of Newfoundland, St. John's, NF, Canada

  • University of Utah School of Medicine, Salt Lake City, UT

  • 1Celgene Corporation Summit NJ United States

  • Hospital Clinico Universitario, Malaga, Spain

  • West Tennessee Research Institute, Jackson, United States

Locations

  • Australia

  • Canada

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • C reactive protein

Drug/Treatment

  • Apremilast

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Celgene Corporation

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved